Monkasta (Montelukast)

Montelukast, the active ingredient in Monkasta, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children by reducing leukotriene‑mediated inflammation.

GNH USA supplies Monkasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Montelukast acts on leukotriene‑driven respiratory conditions. - Asthma: improves control of persistent asthma and reduces exacerbation frequency. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity. - Pediatric asthma: helps maintain symptom control in children with persistent asthma.

Montelukast is generally well tolerated, but several adverse reactions have been reported. Common Side Effects: - Headache: mild to moderate. - Upper respiratory tract infection: nasopharyngitis. - Abdominal pain: stomach discomfort. - Diarrhoea: loose stools. Serious or Rare Side Effects: - Allergic reactions: rash, pruritus or angioedema. - Mood changes: depression, anxiety or suicidal thoughts. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Stevens‑Johnson syndrome: severe skin blistering (rare).

Prec